BNIP3 and pancreatic neoplasm: Epigenetic silencing of the BNIP3 promoter appears to be the most common mechanism explaining down-regulation of BNIP3 during malignant progression in lung, colorectal, hematologic, liver, and pancreatic cancers (194–200) although genomic deletion (201) and repression by specific microRNAs (202) has also been reported.